Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Vancomycin resistant enterococci (VRE) are now considered a global public health issue. In this study, we explored the relationship between vancomycin resistance incidence and various demographic and climatic factors.
Methods: This retrospective study was performed between January 1st, 2014 and December 31st, 2021. Data covering the consumption of vancomycin, the prevalence of vancomycin resistance, and relevant demographics were collected. Spearman's rank correlation, beta regression, and spatial statistical analysis were performed using R version 4.2.2 and ArcGIS version 10.7.
Results: Spearman's rank correlation described the positive relation between vancomycin consumption and the prevalence of vancomycin resistant (VRE). Multiple regression analysis showed that vancomycin consumption, rural population, proportion of population aged ≥65, annual temperature, and bed number in medical institutions per thousand people were significantly correlated with VRE prevalence ( = 56.22, < 0.001; = 0.0002, < 0.001; = 0.06, < 0.001; = -0.07, < 0.001; and = -0.37, < 0.001, respectively).
Conclusions: Vancomycin utilization was the predominant factor contributing to VRE resistance; the effects of rural populations and the proportion of the population aged ≥ 65 were significant but relatively minimal. Annual temperature and the number of beds in medical institutions per thousand people were protective factors against VRE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794159 | PMC |
| http://dx.doi.org/10.1016/j.imj.2024.100159 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Novel Nanozyme-based Coordination Compound for Synergistic Periprosthetic Joint Infection Treatment and Bone Repair.
Adv Healthc Mater
September 2025
Hebei Key Laboratory of Biomaterials and Smart Theranostics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin, 300131, China.
Periprosthetic joint infection (PJI) represents a serious complication following joint arthroplasty, and it often results in implant failure, prolonged morbidity, and additional healthcare burdens. Current clinical strategies for PJI treatment face obstacles, including antibiotic resistance, high recurrence rate, and compromised bone repair. To address these challenges, a novel nanozyme-based coordination compound designated as W-GA-Van@Zn is developed.
View Article and Find Full Text PDFAcute kidney injury and subsequent risk of late-onset infection among extremely low gestational age newborns.
J Perinatol
September 2025
University of Colorado School of Medicine, Department of Pediatrics, Aurora, CO, USA.
Objective: Determine whether acute kidney injury (AKI) is associated with subsequent late-onset infection (LOI) among extremely low gestational age newborns (ELGAN).
Study Design: Secondary analysis of participants in the Preterm Erythropoietin for Neuroprotection Trial. Infants surviving ≥7 days with sufficient serum creatinine data were included.
Therapeutic Efficacy and Drug Metabolism of Griseorhodin A Induced by a Co-culture of Actinomycete Strain TMPU-20A002 and Mycobacterium smegmatis in Silkworm Infection Models.
Chem Pharm Bull (Tokyo)
September 2025
Division of Natural Product Chemistry, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
In screening for antibacterial agents from co-cultures of Mycobacterium smegmatis and microbial resources, such as actinomycetes and fungi, the known hydroxyquinone antibiotic griseorhodin A (1) was isolated from a co-culture of actinomycete strain TMPU-20A002 and M. smegmatis. Compound 1 exhibited antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE), with minimum inhibitory concentrations of 0.
View Article and Find Full Text PDFProtocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).
BMJ Open
September 2025
Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.
Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.
View Article and Find Full Text PDFEsculetin Mitigates MRSA Pathogenicity via Innovative Multitarget Inhibition of Staphylococcus aureus Sortase A, Coagulase, and Von Willebrand Factor-binding Protein.
Int J Antimicrob Agents
September 2025
Department of Pediatric Respiratory, Children's Medical Center, The First Hospital of Jilin University, Changchun, 130021, China. Electronic address:
The global proliferation of antibiotic-resistant Staphylococcus aureus, particularly methicillin-resistant Staphylococcus aureus (MRSA), highlights the urgent need for innovative antivirulence strategies. The redundancy and multiplicity of virulence factors produced by S. aureus necessitate interventions capable of concurrently targeting multiple virulence mechanisms.
View Article and Find Full Text PDF